Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

First Posted Date
2016-01-28
Last Posted Date
2022-08-22
Lead Sponsor
Kansas City Heart Rhythm Institute
Target Recruit Count
246
Registration Number
NCT02666742
Locations
🇺🇸

KCHRF, Overland Park, Kansas, United States

🇺🇸

TCAI, Austin, Texas, United States

🇮🇳

Jayadeva Institute of Medical Sciences, Bengaluru, Karnataka, India

and more 2 locations

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

First Posted Date
2016-01-20
Last Posted Date
2023-03-14
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
122
Registration Number
NCT02659384
Locations
🇳🇱

Leiden University Medical Centre, Leiden, Netherlands

🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

🇬🇧

Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital, London, United Kingdom

and more 9 locations

Adjuvant Low Dose Aspirin in Colorectal Cancer

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2016-01-06
Last Posted Date
2024-03-08
Lead Sponsor
Anna Martling
Target Recruit Count
600
Registration Number
NCT02647099
Locations
🇫🇮

Jorvi Hospital, Espoo, Finland

🇫🇮

Meilahti Tower Hospital, Helsinki, Finland

🇳🇴

Akershus University Hospital, Oslo, Norway

and more 29 locations

Evaluating the Need for Pneumatic Compression Devices

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2015-12-29
Last Posted Date
2020-11-06
Lead Sponsor
West Virginia University
Target Recruit Count
80
Registration Number
NCT02641080
Locations
🇺🇸

WVU Medicine Department of Orthopaedics, Morgantown, West Virginia, United States

Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI

First Posted Date
2015-12-29
Last Posted Date
2018-07-17
Lead Sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Target Recruit Count
222
Registration Number
NCT02640794
Locations
🇨🇦

St Michael's Hospital, Toronto, Ontario, Canada

🇪🇸

Hospital Vall d'Hebron de Barcelona, Barcelona, Spain

🇨🇦

Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada

and more 1 locations

Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization

First Posted Date
2015-12-15
Last Posted Date
2015-12-15
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
240
Registration Number
NCT02630862
Locations
🇮🇹

Civic Hospital, Vascular Surgery Unit, Latina, LT, Italy

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2015-12-01
Last Posted Date
2023-07-28
Lead Sponsor
Atrial Fibrillation Network
Target Recruit Count
2608
Registration Number
NCT02618577
Locations
🇩🇪

Several Sites, Multiple Locations, Germany

🇬🇧

Several, Multiple Locations, United Kingdom

ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-11-30
Last Posted Date
2018-04-17
Lead Sponsor
University of Ioannina
Target Recruit Count
1220
Registration Number
NCT02616497
Locations
🇬🇷

Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina, Greece

Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-11-18
Last Posted Date
2016-05-03
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
40
Registration Number
NCT02607436
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

Aspirin on CTCs of Advanced Breast and Colorectal Cancer

First Posted Date
2015-11-11
Last Posted Date
2015-11-13
Lead Sponsor
Zhejiang Provincial People's Hospital
Target Recruit Count
40
Registration Number
NCT02602938
Locations
🇨🇳

Zhejiang provincial people's hospital, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath